[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-357617-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-357617-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","met-amplified-gastric-cancers-exhibit-co-amplifications-of-braf-cdk6-and-egfr","MET-amplified gastric cancers exhibit co-amplifications of BRAF, CDK6 , and EGFR","","MET-positive gastric cancer shows poor outcomes, and prior efforts to target MET with monoclonal antibodies or tyrosine kinase inhibitors have had limited clinical success. The study investigated additional genetic alterations that could account for poor prognosis and lack of response. Multiregional whole-exome sequencing in discovery cases was complemented by validation using immunohistochemistry, in situ hybridization, and digital droplet PCR.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/met-amplified-gastric-cancers-exhibit-co-amplifications-of-braf-cdk6-and-egfr/357617/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/met-amplified-gastric-cancers-exhibit-co-amplifications-of-braf-cdk6-and-egfr/357617.png","ImageObject",300,407,{"name":42,"@type":43},"Fans","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-25","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are MET-positive gastric cancers associated with poor prognosis?","Question",{"text":63,"@type":64},"MET-positive gastric cancer has a poor prognosis, and this poor outcome has not been adequately explained by limited responses to MET-targeted therapies.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did the researchers identify additional genetic alterations?",{"text":68,"@type":64},"They used multiregional whole-exome sequencing on primary tumors and lymph node metastases in discovery cases, then applied immunohistochemistry, in situ hybridization, and digital droplet PCR in a validation cohort.",{"name":70,"@type":61,"acceptedAnswer":71},"Which co-amplified oncogenes were reported alongside MET?",{"text":72,"@type":64},"Validation found co-amplification of BRAF, CDK6, and EGFR in many MET-amplified cases, often in different combinations, contributing to diagnostic and therapeutic challenges.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},357617,1790932109,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},5909892330395,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","The Journal of Pathology: Clinical Research J Pathol Clin Res July 2026; 12: e70104 Published online in Wiley Online Library (wi[leyonlinelibrary.com](leyonlinelibrary.com). DOI: 10.1002/2056-4538.70104)[).](leyonlinelibrary.com). DOI: 10.1002/2056-4538.70104)[ DOI: 10.1002/2056-4538.70104](leyonlinelibrary.com). DOI: 10.1002/2056-4538.70104)  \nORIGINAL ARTICLE  \nMET-ampliﬁed gastric cancers exhibit co-ampliﬁcations of BRAF, CDK6 , and EGFR  \nSilke Lüschen 1 , Ulrike Ebert 1 , Hans-Michael Behrens 1 , Sandra Krüger 1 , Dita Ulase 1 , Anu Amallraja2,3 , Steffen M. Heckl4, Thomas Becker5, Philip Rosenstiel6 , Tobias Meißner2†  and Christoph Röcken 1 *†   \n1 Department of Pathology, University Hospital Schleswig-Holstein (UKSH), Campus Kiel, Kiel, Germany 2Department of Cancer Genomics, Avera Cancer Institute, Sioux Falls, SD, USA  \n3Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA  \n4Department of Internal Medicine II, Hematology and Oncology, University Hospital Schleswig-Holstein (UKSH), Campus Kiel, Kiel, Germany 5Department of General Surgery, Visceral, Thoracic, Transplantation and Pediatric Surgery, University Hospital Schleswig-Holstein (UKSH), Campus Kiel, Kiel, Germany  \n6Institute for Clinical Molecular Biology, Christian-Albrechts-University, Kiel, Germany  \n*Correspondence to: Christoph Röcken, Department of Pathology, Christian-Albrechts-University, Arnold-Heller-Str. 3, Haus U33, D-24105 Kiel,  \nGermany. E-mail: [christoph.roecken@uksh.de](christoph.roecken@uksh.de)[ ](christoph.roecken@uksh.de)†These authors contributed equally to this work.  \nAbstract  \nMET-positive gastric cancer (GC) has a poor prognosis. In addition, targeting MET with monoclonal antibodies or tyrosine kinase inhibitors had limited success. We searched for additional genetic alterations that might explain the poor outcome of MET-positive GC and lack of response to MET-targeted therapies. Multiregional whole-exome sequencing was performed on primary tumor and lymph node metastasis samples from two MET-ampliﬁed discovery cases. Immunohistochemistry, in situ hybridization, and digital droplet polymerase chain reaction were performed in a validation cohort of 24 MET-ampliﬁed GCs. Whole-exome sequencing found 191 and 166 nonsynonymous mutations, respectively. Only eight genes showed non-synonymous mutations in both cases, including TP53. Copy number variations (CNVs) were found in 18 and 14 autosomes, respectively, most commonly affecting chromosome 7. Since BRAF, CDK6, and EGFR are also localized on chromosome 7, validation studies were performed by ﬂuorescence or chromogenic in situ hybridization, and co-ampliﬁcation was found in 54% of the cases, including two discovery and 24 validation cases. Different combinations were found, for example, CDK6 + MET, EGFR + MET, CDK6 + EGFR + MET, BRAF + CDK6 + EGFR + MET, or BRAF + EGFR + MET. A database search using cBioPortal conﬁrmed our ﬁndings. However, marked intra-and intertumoral heterogeneity was observed, and CNVs were highly variable and spatially separated. MET ampliﬁcation in GC is accompanied by ampliﬁcation of otheroncogenes located on chromosome 7, that is, BRAF, CDK6, and EGFR, in a highly heterogeneous manner leading to substantial intra-and intertumoral heterogeneity. This may cause diagnostic and therapeutic challenges, provoke subclonal evolution, and lead to poor prognosis of MET-ampliﬁed GC and the failure of targeted therapies.  \nKeywords: gastric cancer; mesenchymal-epithelial transition factor (MET); targeted therapy; co-ampliﬁcation; copy number variation  \nReceived 14 December 2025; Revised 20 May 2026; Accepted 18 June 2026 No conﬂicts of interest were declared.  \nIntroduction  \nGastric cancer (GC) is the third leading cause of cancer-related death worldwide (Global Cancer Observatory, 2019; [https://gco.iarc.fr/en](https://gco.iarc.fr/en)). Its prognosis is usually poor, as the tumors are often only diagnosed at an advanced st","cbCaipyIRzgzuVpP","https://ap.wps.com/l/cbCaipyIRzgzuVpP","pdf",45928891,15,"English","# Abstract\n# Introduction","[{\"question\":\"Why are MET-positive gastric cancers associated with poor prognosis?\",\"answer\":\"MET-positive gastric cancer has a poor prognosis, and this poor outcome has not been adequately explained by limited responses to MET-targeted therapies.\"},{\"question\":\"How did the researchers identify additional genetic alterations?\",\"answer\":\"They used multiregional whole-exome sequencing on primary tumors and lymph node metastases in discovery cases, then applied immunohistochemistry, in situ hybridization, and digital droplet PCR in a validation cohort.\"},{\"question\":\"Which co-amplified oncogenes were reported alongside MET?\",\"answer\":\"Validation found co-amplification of BRAF, CDK6, and EGFR in many MET-amplified cases, often in different combinations, contributing to diagnostic and therapeutic challenges.\"}]","MET-amplified gastric cancers exhibit co-amplifications of BRAF, CDK6 , and EGFR | PDF",1790130796,38,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7c9b7d399d4cac27302e379344dcbe50.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5a0974f873b08e77a6da6f388a747af1.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a256abb3a003d8608b0aa7f92a96016a.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cd7cb5d3276e9f161dd42fa773be2619.webp",980,1287]